Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test?

Clinical Endocrinology

Volumn 78, Issue 3, 2013, Pages 358-364

  Pina, Géraldine ^a   Dubois, Séverine ^b   Murat, Arnaud ^c   Berger, Nicole ^d   Niccoli, Patricia ^e   Peix, Jean Louis ^d   Cohen, Régis ^f   Guillausseau, Claudine ^g   Charrie, Anne ^d   Chabre, Olivier ^h   Cornu, Catherine ^a   Borson Chazot, Françoise ^a   Rohmer, Vincent ^b  

^a UNIVERSITÉ LYON 1   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e TIMONE HOSPITAL   (France)

^f AVICENNE HOSPITAL   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; PENTAGASTRIN; PROTEIN RET;

ADOLESCENT; ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CHILD; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALCITONIN; CARCINOMA, MEDULLARY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PENTAGASTRIN; PROSPECTIVE STUDIES; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84872930299     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12001     Document Type: Article

References (35)

1. Cohen, R., Campos, J.M., Salaun, C., et al,. (2000) Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). Journal of Clinical Endocrinology and Metabolism, 85, 919-922. (Pubitemid 32273687)
2. de Groot, J., Kema, I., Breukelman, H., et al,. (2006) Biochemical markers in the follow-up of medullary thyroid cancer. Thyroid, 16, 1163-1170. (Pubitemid 44864492)
3. Costante, G., Durante, C., Francis, Z., et al,. (2009) Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nature Clinical Practice Endocrinology & Metabolism, 5, 35-44.
4. Costante, G., Meringolo, D., Durante, C., et al,. (2007) Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. Journal of Clinical Endocrinology and Metabolism, 92, 450-455.
5. Pacini, F., Schlumberger, M., Dralle, H., et al,. (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology, 154, 787-803. (Pubitemid 43997716)
6. Vierhapper, H., Bieglmayer, C., Kaserer, K., et al,. (2005) Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients thyroid disorders. Thyroid, 15, 1267-1272. (Pubitemid 41821761)
7. Dralle, H., Gimm, O., Simon, D., et al,. (1998) Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World Journal of Surgery 22, 744-750; discussion 750-741.
8. Niccoli-Sire, P., Murat, A., Rohmer, V., et al,. (2001) Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients. Journal of Clinical Endocrinology and Metabolism, 86, 3746-3753. (Pubitemid 32755971)
9. Elisei, R., Romei, C., Renzini, G., et al,. (2012) The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. Journal of Clinical Endocrinology and Metabolism, 97, 426-435.
10. Rohmer, V., Vidal-Trecan, G., Bourdelot, A., et al,. (2011) Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines. Journal of Clinical Endocrinology and Metabolism, 96, E509-E518.
11. Engelbach, M., Gorges, R., Forst, T., et al,. (2000) Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. Journal of Clinical Endocrinology and Metabolism, 85, 1890-1894. (Pubitemid 32269294)
12. Lips, C.J., Hoppener, J.W., &, Thijssen, J.H., (2001) Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. Annals of Clinical Biochemistry, 38, 168-179. (Pubitemid 32429998)
13. Kebebew, E., Ituarte, P.H., Siperstein, A.E., et al,. (2000) Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer, 88, 1139-1148. (Pubitemid 30127676)
14. Modigliani, E., Cohen, R., Campos, J.M., et al,. (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clinical Endocrinology (Oxford), 48, 265-273. (Pubitemid 28137636)
15. Cooper, D.S., Doherty, G.M., Haugen, B.R., et al,. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19, 1167-1214.
16. Doyle, P., Düren, C., Nerlich, K., et al,. (2009) Potency and tolerance of calcitonin stimulation with high dose calcium versus pentagastrin in normal adults. Journal of Clinical Endocrinology and Metabolism, 94, 2970-2974.
17. Colombo, C., Verga, U., Mian, C., et al,. (2012) Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 97, 905-913.
18. Basuyau, J.P., Mallet, E., Leroy, M., et al,. (2004) Reference intervals for serum calcitonin in men, women, and children. Clinical Chemistry, 50, 1828-1830. (Pubitemid 39298017)
19. Kloos, R.T., Eng, C., Evans, D.B., et al,. (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid, 19, 565-612.
20. Niccoli, P., Wion-Barbot, N., Caron, P., et al,. (1997) Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. Journal of Clinical Endocrinology and Metabolism, 82, 338-341. (Pubitemid 27068587)
21. Pacini, F., Castagna, M.G., Brilli, L., et al,. (2008) Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology 19 (Suppl 2), ii99-ii101.
22. Barbot, N., Calmettes, C., Schuffenecker, I., et al,. (1994) Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 78, 114-120.
23. Guyetant, S., Wion-Barbot, N., Rousselet, M.C., et al,. (1994) C-cell hyperplasia associated with chronic lymphocytic thyroiditis: a retrospective quantitative study of 112 cases. Human Pathology, 25, 514-521. (Pubitemid 24173869)
24. d'Herbomez, M., Caron, P., Bauters, C., et al,. (2007) Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. European Journal of Endocrinology, 157, 749-755.
25. Dora, J.M., Canalli, M.H., Capp, C., et al,. (2008) Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature. Thyroid, 18, 895-899.
26. Wang, T.S., Ocal, I.T., Sosa, J.A., et al,. (2008) Medullary thyroid carcinoma without marked elevation of calcitonin: a diagnostic and surveillance dilemma. Thyroid, 18, 889-894.
27. Toledo, S.P., Lourenco, D.M. Jr, Santos, M.A., et al,. (2009) Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo), 64, 699-706.
28. Baloch, Z., Carayon, P., Conte-Devolx, B., et al,. (2003) Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid, 13, 3-126.
29. Milone, F., Ramundo, V., Chiofalo, M.G., et al,. (2011) Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. Clinical Endocrinology (Oxford), 73, 85-88.
30. Pacini, F., Castagna, M.G., Cipri, C., et al,. (2010) Medullary thyroid carcinoma. Clinical Oncology (Royal College of Radiologists (Great Britain)), 22, 475-485.
31. Machens, A., Hauptmann, S., &, Dralle, H., (2008) Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination? Journal of Clinical Endocrinology and Metabolism, 93, 2234-2238. (Pubitemid 351831540)
32. Machens, A., &, Dralle, H., (2007) Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World Journal of Surgery, 31, 957-968. (Pubitemid 46716774)
33. Machens, A., &, Dralle, H., (2009) Prophylactic thyroidectomy in RET carriers at risk for hereditary medullary thyroid cancer. Thyroid, 19, 551-554.
34. Ball, D.W., (2009) American Thyroid Association guidelines for management of medullary thyroid cancer: an adult endocrinology perspective. Thyroid, 19, 547-550.
35. Machens, A., Lorenz, K., &, Dralle, H., (2009) Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. Annals of Surgery, 250, 305-310.